Tags

Type your tag names separated by a space and hit enter

Added diagnostic value of CSF biomarkers in differential dementia diagnosis.
Neurobiol Aging 2010; 31(11):1867-76NA

Abstract

This study aimed to investigate whether cerebrospinal fluid (CSF) biomarkers could have helped the clinician in differential dementia diagnosis in case of clinically ambiguous diagnoses, as compared to autopsy-confirmed dementia diagnosis as gold standard. Twenty-two patients of our autopsy-confirmed dementia population totalling 157 patients had an ambiguous clinical diagnosis at CSF sampling and were included in statistical analysis. CSF levels of β-amyloid peptide (Aβ(1-42)), total tau protein (T-tau) and tau phosphorylated at threonine 181 (P-tau(181P)) were determined. A biomarker-based model was applied to discriminate between AD and NON-AD dementias. AD and NON-AD patients showed no significant differences in Aβ(1-42) and T-tau concentrations, whereas P-tau(181P) concentrations were significantly higher in AD compared to NON-AD patients. The biomarker-based diagnostic model correctly classified 18 of 22 (82%) patients with clinically ambiguous diagnoses. Using a biomarker-based model in patients with clinically ambiguous diagnoses, a correct diagnosis would have been established in the majority of autopsy-confirmed AD and NON-AD cases, indicating that biomarkers have an added diagnostic value in cases with ambiguous clinical diagnoses.

Authors+Show Affiliations

Reference Center for Biological Markers of Memory Disorders, Laboratory of Neurochemistry and Behavior, Institute Born-Bunge, University of Antwerp, Universiteitsplein 1, 2610 Antwerp, Belgium.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

19150153

Citation

Le Bastard, Nathalie, et al. "Added Diagnostic Value of CSF Biomarkers in Differential Dementia Diagnosis." Neurobiology of Aging, vol. 31, no. 11, 2010, pp. 1867-76.
Le Bastard N, Martin JJ, Vanmechelen E, et al. Added diagnostic value of CSF biomarkers in differential dementia diagnosis. Neurobiol Aging. 2010;31(11):1867-76.
Le Bastard, N., Martin, J. J., Vanmechelen, E., Vanderstichele, H., De Deyn, P. P., & Engelborghs, S. (2010). Added diagnostic value of CSF biomarkers in differential dementia diagnosis. Neurobiology of Aging, 31(11), pp. 1867-76. doi:10.1016/j.neurobiolaging.2008.10.017.
Le Bastard N, et al. Added Diagnostic Value of CSF Biomarkers in Differential Dementia Diagnosis. Neurobiol Aging. 2010;31(11):1867-76. PubMed PMID: 19150153.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Added diagnostic value of CSF biomarkers in differential dementia diagnosis. AU - Le Bastard,Nathalie, AU - Martin,Jean-Jacques, AU - Vanmechelen,Eugeen, AU - Vanderstichele,Hugo, AU - De Deyn,Peter Paul, AU - Engelborghs,Sebastiaan, Y1 - 2009/01/15/ PY - 2008/07/09/received PY - 2008/09/26/revised PY - 2008/10/30/accepted PY - 2009/1/20/entrez PY - 2009/1/20/pubmed PY - 2011/2/1/medline SP - 1867 EP - 76 JF - Neurobiology of aging JO - Neurobiol. Aging VL - 31 IS - 11 N2 - This study aimed to investigate whether cerebrospinal fluid (CSF) biomarkers could have helped the clinician in differential dementia diagnosis in case of clinically ambiguous diagnoses, as compared to autopsy-confirmed dementia diagnosis as gold standard. Twenty-two patients of our autopsy-confirmed dementia population totalling 157 patients had an ambiguous clinical diagnosis at CSF sampling and were included in statistical analysis. CSF levels of β-amyloid peptide (Aβ(1-42)), total tau protein (T-tau) and tau phosphorylated at threonine 181 (P-tau(181P)) were determined. A biomarker-based model was applied to discriminate between AD and NON-AD dementias. AD and NON-AD patients showed no significant differences in Aβ(1-42) and T-tau concentrations, whereas P-tau(181P) concentrations were significantly higher in AD compared to NON-AD patients. The biomarker-based diagnostic model correctly classified 18 of 22 (82%) patients with clinically ambiguous diagnoses. Using a biomarker-based model in patients with clinically ambiguous diagnoses, a correct diagnosis would have been established in the majority of autopsy-confirmed AD and NON-AD cases, indicating that biomarkers have an added diagnostic value in cases with ambiguous clinical diagnoses. SN - 1558-1497 UR - https://www.unboundmedicine.com/medline/citation/19150153/Added_diagnostic_value_of_CSF_biomarkers_in_differential_dementia_diagnosis_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0197-4580(08)00394-1 DB - PRIME DP - Unbound Medicine ER -